NICE issues Final Appraisal Determination for Vertex’s Orkambi to treat cystic fibrosis

The National Institute for Health and Care Excellence (NICE) in the UK has issued a Final Appraisal Determination (FAD) for Massachusetts-based pharmaceutical company Vertex’s Orkambi (lumacaftor / ivacaftor), as a new therapy for treating cystic fib…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news